Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer

NCT04385641 is registered in ClinicalTrials.gov with Shandong Golden Brick Biotechnology Co., Ltd. as lead sponsor.

NCT NCT04385641
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04385641 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer
Lead sponsor
Shandong Golden Brick Biotechnology Co., Ltd.
Phase
Not applicable
Overall status
Unknown status
Start date
October 8, 2019
Completion date
October 8, 2022
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced gastric cancer, gastroesophageal cancer